Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.71 |
| ▸ | EGFR | P00533 | 7/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.53 |
| ▸ | KIF5B | P33176 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951030 | 0.93 | ENPP1 (0.73) | ENPP1EGFRRETKIF5BATM | |
| SCHEMBL1013051 | 0.86 | ENPP1 (0.79) | ENPP1EGFRKDRCSF1R | |
| SCHEMBL1015576 | 0.86 | ENPP1 (0.79) | ENPP1EGFRKDRCSF1R | |
| SCHEMBL30864338 | 0.86 | ENPP1 (0.79) | ENPP1EGFRKDRCSF1R | |
| SCHEMBL31620798 | 0.86 | ENPP1 (0.79) | ENPP1EGFRKDRCSF1R | |
| SCHEMBL4375574 | 0.86 | ENPP1 (0.62) | ENPP1EGFRKDRCSF1R | |
| SCHEMBL13299050 | 0.85 | ENPP1 (0.86) | ENPP1EGFRKDR | |
| SCHEMBL16760503 | 0.85 | ENPP1 (0.77) | ENPP1EGFRRETKIF5BKDR | |
| SCHEMBL8649615 | 0.85 | ENPP1 (0.86) | ENPP1EGFRKDR | |
| Hydrochloric Acid SCHEMBL28825385 | 0.85 | ENPP1 (0.77) | ENPP1EGFRKDRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514460-B2 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2009-04-07 | — | — | US | disclosed |
| EP-1885719-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006066795-A1 | 2,5- AND 2,6-DISUBSTITUTED BENZAZOLE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | 4SC AG (DE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135782-A1 | Benzazole analogues and uses thereof | 4SC AG (DE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135782-A1 | Benzazole analogues and uses thereof | DCK, SBK3, DAPK3 | ENPP1 1457/4885EGFR 437/4885RET 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.